A 22-year-old gravida 3, para 2, a previously healthy white female, presented to her doctor with heavy uterine bleeding and received a diagnosis of missed abortion after workup. She underwent dilation and curettage (D&C), but continued to have uterine bleeding that resulted in a call to EMS and transport to a medical facility. The blood loss was estimated to be approximately 700 mL. She underwent a second D&C that resulted in more severe bleeding. An immediate sonogram demonstrated a mass in the endometrium, and high-color-flow Doppler signal was detected there as well, suggesting the possibility of a pseudoaneurysm. The patient was referred from an outside facility to the Interventional Radiology service for angiography with possible embolization, since she wanted to preserve fertility if possible.
Owing to the size of the pseudoaneurysm and its location, we attempted to obtain proximal and distal control with embolization. Attempts to pass a Tracker (Target Therapeutics, Fremont, CA, USA) microcatheter distal to the pseudoaneurysm were complicated by development of a uterine-artery spasm.
A second attempt was successful with a flow-directed microcatheter, Marathon (ev3 Endovascular, Inc. Plymouth, MN), commonly used for intracranial vascular malformation catheterizations. An X-Pedion (ev3 Endovascular, Inc. Plymouth, MN) microwire successfully negotiated the microcatheter distal to the pseudoanerysm in the uterine artery. The angiogram obtained from the microcatheter revealed reflux of the contrast to the pseudoaneurysm from the distal artery (Fig. 4) .
The inner diameter of the microcatheter is 0.013 in. and not suitable for thrombogenic coils to deliver; therefore, we decided to use Onyx 18 (ev3 Endovascular, Inc. Plymouth, MN) as the embolization agent. The Onyx® was slowly injected to occlude the uterine artery distal to the pseudo- aneurysm, at the site of the pseudoaneurysm, and more proximally with good control of the flow; this obliterated the parent artery without leakage into the pseudoaneurysm, thus avoiding mass effect in the myometrium (Fig. 5 ).
Followup angiography demonstrated a good result without opacification of the pseudoaneurysm with contrast (Figs. 6, 7). Delayed angiography of the right uterine artery demonstrated no cross-filling of the pseudoaneurysm (Fig.  8 ).
The patient was admitted to the hospital following the procedure and had an uneventful hospital course with resolution of the hemorrhage. She experienced mild to moderate cramping during the night; the next morning, that was controlled with a 30mg dose of ketorolac and NSAIDs by mouth. She was discharged home the following day in good condition, with a two-week followup with her primary physician. She maintained a stable hematocrit level and had no further uterine bleeding at the time of followup.
Discussion
Uterine bleeding is usually treated with D&C following a missed abortion if serial quantitative β-hcg levels fail to drop at an appropriate rate. A second D&C may be performed if the elevated serum β-hcg persists. Definitive treatment of these conditions is often hysterectomy after conservative workup and treatment.
Pseudoaneurysm treatment with Onyx® has been described in the renal arteries by Rennert et al (1) and Zelenak et al (2) and in the subclavian artery by Amiridze, Trivedi, and Kshitij (3). 100% success of the procedure for embolization of the pseudoaneurysm is documented, with an average 21-month followup of no recurrence of renal bleeding or AV fistulas in the selected patients. Experiences of treatment of peripheral aneurysms in the internal iliac and thoracic collateral arteries and in peripheral pseudo- aneurysms in a lumbar artery and a renal artery are described by Vanninen and Manninen while using a combination of Onyx® and a stent and Onyx® with balloon assistance (4) .
Pseudoaneurysms of the uterine artery are well described in postpartum hemorrhage and after uterine curettage that can result in significant uterine bleeding; they are effectively treated with transcatheter arterial embolization (5). These are commonly discovered after the procedure when the hemorrhage fails to resolve; ultrasound of the pelvis demonstrates focal areas of increased color or swirling flow within the uterus or myometrium.
In a case report submitted by Padavala and Ahluwalia (6), pseudoaneurysm of the left uterine artery was discovered and treated with transcatheter arterial embolization with polyvinyl alcohol particles. Recurrence of the pseudoaneurysm occurred within 72 hours of the procedure that precipitated the hysterectomy.
Use of Onyx® for embolization in the uterine artery is not well described. The advantage of Onyx® compared to PVA particles is the permanence of the media and the good control of the Onyx® during delivery. The Onyx® is delivered under controlled injection with direct visualization of the polymer during application (instead of flow direction, as with PVA). The result of Onyx® application is a permanent solid plug that takes the shape of the vessel or defect it is injected into.
Immediately after injection into the bloodstream, Onyx® begins to solidify from the outside surface to the inside as the carrier solvent, DMSO (dimethyl-sulfoxide), dissipates into the blood. Onyx® must be injected through DMSOcompatible catheters (for example, Marathon TM, Echelon TM, Rebar®, or UltraFlow TM HPC -ev3 Endovascular, Inc. Plymouth, MN). Since Onyx® solidification occurs when injected into the bloodstream, multiple small controlled injections for a slow, controlled occlusion of the target vessel are possible. VanRooij, Sluzewski, and Beute (7) report possible procedure times greater than 60 minutes. Given the potential of a lengthy procedure, radiation dose must be considered.
Onyx® is available in two concentrations: Onyx 18 (6% EVOH) and Onyx 34 (8% EVOH). Onyx 34 has a higher viscosity than Onyx 18 and is commonly used for higherflow conditions (such as those that occur in a nidus) or for larger-vessel diameters. The higher viscosity of Onyx 34 allows the building of an embolic base at the catheter tip before injection of Onxy 18 to gain control of the embolic target. Injection of Onyx 18 allows for more distal travel of Onyx® into smaller portions of the target vessels. The potential complications of liquid embolic agents are the same for Onyx® as for other liquid embolic agents, including nontarget embolization and the possibility of gluing the catheter to the vessel. An additional risk of skin discoloration is present if the embolization is near the skin surface, as Onyx® has a dark color. We used Onyx 18 for injection into the uterine-artery pseudoaneurysm because of the small vessel size and because it could penetrate more distally and prevent back-filling of the pseudoaneurysm from collateral vessels.
No long-term data is available for the effect on fertility after use of Onyx® in the uterine arteries.
